MARKET

SYRE

SYRE

Spyre Therapeutics
NASDAQ
23.58
+3.17
+15.53%
After Hours: 23.58 0 0.00% 16:00 02/23 EST
OPEN
20.96
PREV CLOSE
20.41
HIGH
23.74
LOW
20.13
VOLUME
746.74K
TURNOVER
0
52 WEEK HIGH
28.66
52 WEEK LOW
2.660
MARKET CAP
850.23M
P/E (TTM)
-0.3105
1D
5D
1M
3M
1Y
5Y
Spyre Therapeutics: Statement of changes in beneficial ownership of securities
Press release · 3d ago
Weekly Report: what happened at SYRE last week (0212-0216)?
Weekly Report · 5d ago
Spyre Therapeutics: Statement of acquisition of beneficial ownership by individuals
Press release · 02/14 15:49
Weekly Report: what happened at SYRE last week (0205-0209)?
Weekly Report · 02/12 11:11
Here's Why Spyre Therapeutics (SYRE) Could be Great Choice for a Bottom Fisher
NASDAQ · 02/06 14:55
Spyre Therapeutics Revamps Governance and Fiscal Year
TipRanks · 02/06 09:17
Spyre Therapeutics Announces Board Changes and Compensation Updates
Spyre Therapeutics has announced the appointment of Mark McKenna to the Board. McKenna will replace Alison Lawton, who will step down on February 1, 2024. The company has also amended its CEO's employment agreement to increase severance benefits. McKenna brings a wealth of experience to the board.
TipRanks · 02/06 09:16
Spyre Therapeutics Enhances Protection for Executives and Board
TipRanks · 02/06 09:16
More
About SYRE
Spyre Therapeutics, Inc., formerly Aeglea BioTherapeutics, Inc., is a biotechnology company. The Company focuses to create the next generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. Its pipeline includes extended half-life antibodies targeting α4β7, tumor necrosis factor-like ligand 1A (TL1A), and IL-23. Its pipeline programs include SPY001, SPY002, SPY003, SPY004, SPY120, SPY130, and SPY230. Its advanced product candidate, SPY001, is designed to be a highly potent, selective, and fully humanized monoclonal immunoglobulin G1 antibody that binds selectively to the α4β7 integrin. Its co-lead product candidate, SPY002 is designed to be a highly potent, highly selective, and fully humanized monoclonal antibody that binds to TL1A. SPY003 is a highly potent and selective monoclonal antibody product candidate targeting the p19 subunit of IL-23.

Webull offers Spyre Therapeutics Inc stock information, including NASDAQ: SYRE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SYRE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SYRE stock methods without spending real money on the virtual paper trading platform.